Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck Serono International SA. An Affiliate of Merck KGaA, Darmstadt, Germany
Update Il y a 4 ans
A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) to Raptiva 1mg/kg/week therapy
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whlist tapering the initial systemic therapy or phototherapy d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
Update Il y a 4 ans
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course
The primary objective of the study is to evaluate the efficacy of three doses of atacicept to reduce CNS inflammation in subjects with RMS as assessed by frequent MRI.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 5 ans
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia
The primary objective of this study is to demonstrate efficacy of 1 mg Sarizotan HCl b.i.d. after 12 weeks and after 24 weeks (maintenance of efficacy) in the treatment of dyskinesia in Parkinson's di...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Phase II study with Stimuvax® (L-BLP25 liposome vaccine) in subjects with either chemotherapy-naive, slowly progressive asymptomatic multiple myeloma or with stage II/ III multiple myeloma following chemotherapy
Primary objective: To ascertain whether vaccination with L-BLP25 induces a MUC1-specific T-cell response in subjects with either: Chemotherapy-naïve, slowly progressive, asymptomatic MM with rising ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuximab in subjects with recurrent/metastatic squamous cell cancer of the head and neck
Progression Free Survival
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Clinical trial to investigate cetuximab in combination with capecitabine and cisplatin versus capecitabine and cisplatin alone as first-line treatment for patients with advanced gastric cancer. Klinikai vizsgálat a capecitabine-nel és cisplatinnal kombinált cetuximab terápia kiértékelésére az önmagában adott capecitabine-nel és cisplatinnal összehasonlítva mint elsővonalbeli terápia előrehaladott gyomorrákban szenvedő betegek körében
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with XP chemotherapy regimen has a clinically relevant benefit for subjects with advanced gastric...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis Estudio de la eficacia y seguridad de M2951 en la esclerosis múltiple recidivante
The primary objective is to evaluate the efficacy and dose-response of M2951 on the number of gadolinium-positive (Gd+) T1 MRI lesions versus placebo after 24 weeks of treatment. El objetivo pri...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis
The primary objective of this trial is to evaluate the efficacy of plovamer acetate (0.5 mg, 3 mg, 10 mg and 20 mg) administered as weekly SC injection vs. Copaxone 20 mg administered as daily SC inje...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Allergopharma Joachim Ganzer KG an afilliate of Merck KGaA, Darmstadt
Update Il y a 4 ans
A multicentre randomised placebo-controlled, double-blind clinical trial for eval¬ua¬tion of safety and efficacy of pre-seasonal specific immunotherapy with a hypoallergenic extract of a 6 grass and rye (Grasses plus Rye) pollen mixture in patients with rhinoconjunctivitis +/- asthma bronchiale
The aim of this CT is to prove the hypothesis that the allergoid preparation of an extract of a grasses plus rye pollen mixture is suitable for an efficacious treatment of grass pollen allergic patien...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
Next